Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1701616 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing precision: A predictive model for Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative Ga-DOTATATE PET and clinicopathological biomarkers.
Theranostics
July 2024
Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
Article Synopsis
- This study investigates how specific quantitative measurements from SSTR-PET imaging and clinical biomarkers affect the progression-free survival (PFS) and overall survival (OS) of neuroendocrine tumor (NET) patients undergoing peptide receptor radionuclide therapy (PRRT).
- A total of 91 NET patients were analyzed, revealing that larger tumor volumes, especially in bones and the liver, correlate with shorter survival times, and that tumors with low SSTR uptake negatively impact patient outcomes.
- Elevated levels of the biomarkers chromogranin A and alkaline phosphatase were linked to worse survival, as well as a higher number of previous treatments and tumor origin, with midgut tumors associated with better PFS compared to pancreatic or unknown primary tumors.
Acute Disseminated Intravascular Coagulation Precipitated by Lu-Dotatate in Metastatic Midgut Neuroendocrine Tumor: A Case Report.
J Gastrointest Cancer
December 2023
Department of Medicine, Rutgers Robert Wood Johnson Medical School, 125 Patterson Street, New Brunswick, NJ, 08901, USA.
[Indications and Practice of a New Radionuclide Therapy, 177Lu-DOTATATE in Japan].
Gan To Kagaku Ryoho
August 2022
Dept. of Radiation Oncology, Yokohama City University Graduate School of Medicine.
Peptide receptor radionuclide therapy(PRRT)is a pioneer drug in the rapid development of radio-theranostics, and a paradigm-shifting approach to treat neuroendocrine tumor( NET). The NETTER-1 trial for NETs of the midgut is currently the only global phase Ⅲ prospective clinical trial demonstrating the efficacy and safety of PRRT. In Japan, phase Ⅰ and Ⅰ/Ⅱ trials for lung and gastroenteropancreatic NETs were also conducted, and regulatory approval was granted in June of 2021.
View Article and Find Full Text PDFSafety and response after peptide receptor radionuclide therapy with Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial.
J Hepatobiliary Pancreat Sci
April 2022
Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Background: The present prospective phase 1/2 study aimed to elucidate the efficacy and safety of Lu-DOTATATE (four cycles of 7.4 GBq) in Japanese patients with unresectable, progressive neuroendocrine tumors (NETs).
Methods: From April 2018 to October 2020, 15 patients with advanced NETs (five midgut, eight pancreatic, and two lung NETs) were enrolled.
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
December 2021
Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, Netherlands.
Background: The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide alone in patients with advanced midgut neuroendocrine tumours. Here, we report the prespecified final analysis of overall survival and long-term safety results.
Methods: This open-label, randomised, phase 3 trial enrolled patients from 41 sites in eight countries across Europe and the USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!